Status:
COMPLETED
Clinical Application of Multi-modal Sentinel Lymph Node Staining Method in Breast Cancer Patients After Neoadjuvant Chemotherapy
Lead Sponsor:
National Cancer Center, Korea
Conditions:
Sentinel Lymph Node Biopsy
Neoadjuvant Therapy
Eligibility:
FEMALE
20+ years
Phase:
NA
Brief Summary
This clinical trial aimed to confirm the effectiveness of sentinel lymph node surgery by determining the lymph node identification rate using multimodal sentinel lymph node marker methods in patients ...
Detailed Description
After NAC, the sentinel lymph node (SLN) identification rate is lower, and it has a higher false-negative rate than that in early-stage breast cancer. As appropriate SLN surgery directly affects the t...
Eligibility Criteria
Inclusion
- The patient with locally advanced breast cancer who achieved neoadjuvant chemotherapy
- Confirmed operability with imaging study after neoadjuvant chemotherapy
- Age over 20 years old
- ECOG Performance status : 0-2
- The patient with written informed consent form
Exclusion
- The patient with previous ipsilateral breast cancer history
- The patinet with previous ipsilateral axillary surgical procedure (e.g. excisional or incisional biopsy, axillary dissection)
- The patient without neoadjuvant chemotherapy
- Inoperable imaging study after neoadjuvant chemotherapy
- Inflammatory breast cancer
- Pregnant patient
Key Trial Info
Start Date :
May 4 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 2 2024
Estimated Enrollment :
348 Patients enrolled
Trial Details
Trial ID
NCT06212440
Start Date
May 4 2021
End Date
October 2 2024
Last Update
March 13 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
National Cancer Center
Goyang-si, Gyeonggi-do, South Korea, 410-769
2
National cancer center
Goyang-si, Gyeonggi-do, South Korea, 82